Shire’s SHP626 (Volixibat) Receives FDA Fast Track for Adults who have NASH with Liver Fibrosis

Shire’s SHP626 (Volixibat) Receives FDA Fast Track for Adults who have NASH with Liver Fibrosis

Shire’s SHP626 (Volixibat) Receives FDA Fast Track Designation for an Investigational Treatment for Adults who have Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis July 29, 2016 Lexington,... Monday HCV News Ticker- Hepatitis C: Coffee,...

Close